Corcept Therapeutics Inc (CORT) stock
Close on Nov 13, 2026Market cap $7.88BP/E 173.7Yield –
Corcept Therapeutics Inc grew revenue 16.0% to $830.81M over the twelve months to Jun 30, 2026. Operating income fell 93.7% to $6.41M, moving the operating margin from 14.2% to 0.8%. Free cash flow was $106.92M, down 40.8% from a year earlier. At the latest close the market valued the company at $7.88B, 173.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $7.88B
- P/E ratio
- 173.7
- Price to sales
- 9.49
- Price to book
- 11.17
- Dividend yield
- –
- Free cash flow yield
- 1.36%
Fundamentals
- Revenue
- $830.81M
- Net income
- $55.18M
- EPS, diluted
- $0.42
- Free cash flow
- $106.92M
- Book value per share
- $5.96
- Diluted shares
- 118M
Trading
- Next earnings
- Feb 23, 2027 (estimated, after the close)
- Previous close
- $73.71
- Open
- $73.87
- Day's range
- $71.18 – $74.68
- Volume
- 1,112,931
- Average volume (20 days)
- 1,306,315
- Index membership
- S&P SmallCap 600, Russell 1000 (since Jun 2025), Russell 3000
- Beta (5 years)
- 0.58
- 52-week range
- $28.66 – $126.38
- RSI (14 days)
- 26.1
- Volatility (1 year)
- 83.3%
- Relative volume
- 0.89×
- WACC
- 8.0%
On 1 of our idea list: Quality compounders
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | CORT | S&P 500 | Difference | CORT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -38.1% | -3.0% | −35.0 pts | ||
| 3 months | -34.0% | -2.8% | −31.2 pts | ||
| Year to date | +109.6% | +11.5% | +98.1 pts | ||
| 1 year | -3.7% | +13.5% | −17.2 pts | ||
| 3 years | +193.9% | +77.7% | +116.2 pts | +43.2% | +21.1% |
| 5 years | +217.1% | +72.6% | +144.5 pts | +26.0% | +11.5% |
| 10 years | +650.4% | +308.2% | +342.3 pts | +22.3% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Corcept Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- Results
- News
About Corcept Therapeutics
Pharmaceutical Preparations
The company is a commercial-stage biopharmaceutical organization focused on discovering and developing treatments for severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its core scientific approach involves modulating cortisol activity using proprietary compounds that target the glucocorticoid receptor. The company markets Korlym and an authorized generic mifepristone product in the United States to treat patients diagnosed with hypercortisolism, or Cushing’s syndrome. In addition to commercial therapies, its research pipeline includes investigational selective modulators such as relacorilant for endocrine disorders and solid tumors, miricorilant for metabolic dysfunction-associated steatohepatitis, and dazucorilant for amyotrophic lateral sclerosis. The primary customers are patients prescribed these therapies through physicians and specialized pharmacy channels.
Company profile, executives and historyCorcept Therapeutics stock: common questions
What is Corcept Therapeutics's stock price?
CORT closed at $72.94 on Nov 13, 2026, down 1.04% on the day. Over the past 52 weeks it traded between $28.66 and $126.38.
What is Corcept Therapeutics's market cap?
Corcept Therapeutics was worth $7.88B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is CORT's P/E ratio?
CORT trades at 173.7 times earnings, based on diluted earnings per share of $0.42 over the twelve months to Jun 30, 2026.
How much revenue does Corcept Therapeutics make?
Corcept Therapeutics reported revenue of $830.81M for the twelve months to Jun 30, 2026, up 16.0% from a year earlier.
Does Corcept Therapeutics pay a dividend?
No. Corcept Therapeutics has not paid a cash dividend over the last twelve months.
When does Corcept Therapeutics report earnings next?
Corcept Therapeutics is expected to report Q4 FY2026 results on Feb 23, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CORT stock performed over the past year?
Including dividends, CORT returned -3.7% over the past year, against +13.5% for the S&P 500.
How many CORT shares are sold short?
9M shares were sold short at the latest FINRA report, 9.86% of the float, or 8.1 days of average trading volume.
Who are Corcept Therapeutics's competitors?
Companies most similar to Corcept Therapeutics by business, industry and size include XERS, IONS, MDGL, MIRM, BBIO.
See a number that looks wrong?